215 related articles for article (PubMed ID: 12121920)
1. Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo[2,3-d]pyrimidines does not correlate with antiviral activity.
Evers DL; Breitenbach JM; Borysko KZ; Townsend LB; Drach JC
Antimicrob Agents Chemother; 2002 Aug; 46(8):2470-6. PubMed ID: 12121920
[TBL] [Abstract][Full Text] [Related]
2. Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus.
Jacobson JG; Renau TE; Nassiri MR; Sweier DG; Breitenbach JM; Townsend LB; Drach JC
Antimicrob Agents Chemother; 1999 Aug; 43(8):1888-94. PubMed ID: 10428908
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and ++thiosangivamycin: influence of various 7-substituents on antiviral activity.
Renau TE; Wotring LL; Drach JC; Townsend LB
J Med Chem; 1996 Feb; 39(4):873-80. PubMed ID: 8632411
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of olomoucine II.
Krystof V; Lenobel R; Havlícek L; Kuzma M; Strnad M
Bioorg Med Chem Lett; 2002 Nov; 12(22):3283-6. PubMed ID: 12392733
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines.
Pudlo JS; Nassiri MR; Kern ER; Wotring LL; Drach JC; Townsend LB
J Med Chem; 1990 Jul; 33(7):1984-92. PubMed ID: 2163454
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
[TBL] [Abstract][Full Text] [Related]
8. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors.
Diwan P; Lacasse JJ; Schang LM
J Virol; 2004 Sep; 78(17):9352-65. PubMed ID: 15308730
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
[TBL] [Abstract][Full Text] [Related]
10. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins.
Schang LM; Rosenberg A; Schaffer PA
J Virol; 2000 Mar; 74(5):2107-20. PubMed ID: 10666240
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins.
Schang LM; Bantly A; Knockaert M; Shaheen F; Meijer L; Malim MH; Gray NS; Schaffer PA
J Virol; 2002 Aug; 76(15):7874-82. PubMed ID: 12097601
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and anti-DNA viral activities in vitro of certain 2,4-disubstituted-7-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)pyrrolo[2,3-d d pyrimidine nucleosides.
Bhattacharya BK; Ojwang JO; Rando RF; Huffman JH; Revankar GR
J Med Chem; 1995 Sep; 38(20):3957-66. PubMed ID: 7562929
[TBL] [Abstract][Full Text] [Related]
14. Activity of acyclic halogenated tubercidin analogs against human cytomegalovirus and in uninfected cells.
Nassiri MR; Turk SR; Birch GM; Coleman LA; Hudson JL; Pudlo JS; Townsend LB; Drach JC
Antiviral Res; 1991 Sep; 16(2):135-50. PubMed ID: 1665958
[TBL] [Abstract][Full Text] [Related]
15. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.
Schang LM; Phillips J; Schaffer PA
J Virol; 1998 Jul; 72(7):5626-37. PubMed ID: 9621021
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: the effect of certain 4- and 4,6-substituents on the antiviral activity of pyrrolo[2,3-d]pyrimidines.
Renau TE; Kennedy C; Ptak RG; Breitenbach JM; Drach JC; Townsend LB
J Med Chem; 1996 Aug; 39(18):3470-6. PubMed ID: 8784444
[TBL] [Abstract][Full Text] [Related]
17. Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors.
Moravcová D; Krystof V; Havlícek L; Moravec J; Lenobel R; Strnad M
Bioorg Med Chem Lett; 2003 Sep; 13(18):2989-92. PubMed ID: 12941318
[TBL] [Abstract][Full Text] [Related]
18. Varicella-zoster virus IE63 protein phosphorylation by roscovitine-sensitive cyclin-dependent kinases modulates its cellular localization and activity.
Habran L; Bontems S; Di Valentin E; Sadzot-Delvaux C; Piette J
J Biol Chem; 2005 Aug; 280(32):29135-43. PubMed ID: 15955820
[TBL] [Abstract][Full Text] [Related]
19. 2,6,8,9-tetrasubstituted purines as new CDK1 inhibitors.
Moravec J; Krystof V; Hanus J; Havlícek L; Moravcová D; Fuksová K; Kuzma M; Lenobel R; Otyepka M; Strnad M
Bioorg Med Chem Lett; 2003 Sep; 13(18):2993-6. PubMed ID: 12941319
[TBL] [Abstract][Full Text] [Related]
20. Improved synthesis and biological evaluation of an acyclic thiosangivamycin active against human cytomegalovirus.
Renau TE; Nassiri MR; Swayze EE; Kern ER; Townsend LB; Drach JC
Antiviral Res; 1992 Jul; 19(1):15-28. PubMed ID: 1332597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
